CXCL13 and COVID-19: Moreover, it has been found that patients with severe COVID-19 produce higher serum levels of CXCL13 and increased frequencies of ASCs and TFH cells, and increased production of the specific antibodies of the RBD of SARS-CoV-2, compared to those with moderate disease [62].